Anxiety Disorders

Neurology
7
Pipeline Programs
7
Companies
9
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
4
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
DULOXETINE HYDROCHLORIDEApproved
duloxetine hydrochloride
Unknown Company
oral2013

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
3
DuloxetinePhase 31 trial
Duloxetine HydrochloridePhase 31 trial
duloxetine hydrochloridePhase 31 trial
Active Trials
NCT00122850Completed480Est. Nov 2005
NCT00122863Completed380Est. Mar 2007
NCT00122824Completed480Est. Sep 2005
Teva
TevaIsrael - Petach Tikva
1 program
1
GabitrilPhase 31 trial
Active Trials
NCT00214994CompletedEst. Dec 2006
Novartis
NovartisBASEL, Switzerland
1 program
1
XBD173Phase 21 trial
Active Trials
NCT00108836Completed400Est. May 2006
UP
UCB PharmaBelgium - Brussels
1 program
1
levetiracetamPhase 21 trial
Active Trials
NCT00612859Completed217Est. Jun 2004
One Biosciences
One BiosciencesFrance - Paris
1 program
Effortful Control CampN/A1 trial
Active Trials
NCT03093376CompletedEst. Oct 2020
Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
1 program
Therapy Assistance OnlineN/A1 trial
Active Trials
NCT03390218UnknownEst. Dec 2018
Pfizer
PfizerNEW YORK, NY
1 program
remission prevalence of generalized anxiety disorderN/A1 trial
Active Trials
NCT01788553Completed750Est. Mar 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TevaGabitril
Boehringer IngelheimDuloxetine Hydrochloride
Boehringer IngelheimDuloxetine
Boehringer Ingelheimduloxetine hydrochloride
NovartisXBD173
UCB Pharmalevetiracetam
Connect BiopharmaTherapy Assistance Online
One BiosciencesEffortful Control Camp
Pfizerremission prevalence of generalized anxiety disorder

Clinical Trials (9)

Total enrollment: 2,707 patients across 9 trials

NCT00214994TevaGabitril

Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.

Start: Jan 2005Est. completion: Dec 2006
Phase 3Completed
NCT00122863Boehringer IngelheimDuloxetine Hydrochloride

Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder

Start: Jan 2005Est. completion: Mar 2007380 patients
Phase 3Completed
NCT00122850Boehringer IngelheimDuloxetine

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

Start: Oct 2004Est. completion: Nov 2005480 patients
Phase 3Completed
NCT00122824Boehringer Ingelheimduloxetine hydrochloride

Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder

Start: Jun 2004Est. completion: Sep 2005480 patients
Phase 3Completed
NCT00108836NovartisXBD173

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Start: Mar 2005Est. completion: May 2006400 patients
Phase 2Completed
NCT00612859UCB Pharmalevetiracetam

Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)

Start: Sep 2003Est. completion: Jun 2004217 patients
Phase 2Completed
NCT03390218Connect BiopharmaTherapy Assistance Online

TAO Outpatient Trial for Anxiety and Depression

Start: Jan 2018Est. completion: Dec 2018
N/AUnknown
NCT03093376One BiosciencesEffortful Control Camp

Neurally Targeted Interventions to Reduce Early Childhood Anxiety

Start: Mar 2017Est. completion: Oct 2020
N/ACompleted
NCT01788553Pfizerremission prevalence of generalized anxiety disorder

Study Of Remission In Patients Treated For Generalized Anxiety Disorder

Start: Mar 2006Est. completion: Mar 2007750 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)